TY - JOUR
T1 - International consensus recommendations for management of new onset refractory status epilepticus including febrile infection-related epilepsy syndrome
T2 - Statements and supporting evidence
AU - the International NORSE Consensus Group
AU - Wickstrom, Ronny
AU - Taraschenko, Olga
AU - Dilena, Robertino
AU - Payne, Eric T.
AU - Specchio, Nicola
AU - Nabbout, Rima
AU - Koh, Sookyong
AU - Gaspard, Nicolas
AU - Hirsch, Lawrence J.
AU - Auvin, Stephane
AU - van Baalen, Andreas
AU - Beghi, Ettore
AU - Benseler, Susanne M.
AU - Bergin, Peter
AU - Bleck, Tom
AU - Brunklaus, Andreas
AU - Caraballo, Roberto H.
AU - Cervenka, Mackenzie
AU - Costello, Daniel
AU - Drislane, Frank
AU - Farias-Moeller, Raquel
AU - Gallantine, William
AU - Gilmore, Emily
AU - Gofton, Teneille
AU - Jimenez, Maria Angeles Perez
AU - Hocker, Sara
AU - Kaliakatsos, Marios
AU - Kellogg, Marissa
AU - Lee, Jong Woo
AU - Loddenkemper, Tobias
AU - Meletti, Stefano
AU - Mizugushi, Masashi
AU - Muscal, Eyal
AU - Riviello, James J.
AU - Rosenthal, Eric S.
AU - Rossetti, Andrea O.
AU - Ruegg, Stefan
AU - Said, Rana
AU - Sculier, Claudine
AU - Schmitt, Sarah
AU - Schuele, Stephan
AU - Stredny, Coral
AU - Trinka, Eugen
AU - Wainwright, Mark
AU - VanHaerents, Stephen
AU - Wells, Elisabeth
AU - Wirrell, Elaine
AU - Zuberi, Sameer M.
N1 - Funding Information:
R.W. has served on scientific advisory boards for GW Pharma and Octapharma; and has received speaker honoraria from Eisai and Sanofi. O.T. was supported by a research grant from the National Institutes of Health (P20GM130447). R.D. has received a speaker honorarium fee from Sobi. E.T.P. has received a speaker honorarium from Eisai. S.K. has served on scientific advisory boards for Zogenix and Neurelis. L.J.H. has received consultation fees for advising from Accure, Aquestive, Ceribell, Eisai, Marinus, Medtronic, Neurelis, Neuropace, and UCB; royalties from Wolters‐Kluwer for authoring chapters for and from Wiley for coauthoring the book by Hirsch and Brenner; and honoraria for speaking from Neuropace, Natus, and UCB. NS has served on scientific advisory boards for GW Pharma, BioMarin, Arvelle, Marinus, and Takeda; has received speaker honoraria from Eisai, BioMarin, LivaNova, and Sanofi; and has served as an investigator for Zogenix, Marinus, BioMarin, UCB, and Roche. R.N. and N.G. have no disclosures for this study. The present study is not industry‐sponsored. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. UpToDate–Neurology Atlas of EEG in Critical Care
Funding Information:
The authors wish to thank Nora Wong of the NORSE Institute for valuable input in development of the survey and Ida Wickström for collating and compiling all online data. Study funding: R.W. was supported by Region Stockholm (clinical research appointment) and by research grants from StratNeuro, Karolinska Institute. O.T. was supported by research grants from the National Institutes of Health (P20GM130447) and an American Epilepsy Society–NORSE Institute Seed grant. S.K. was supported by an American Epilepsy Society–NORSE Institute Seed grant. R.D. was supported by the Scientific Institute for Research and Health Care Foundation Milan Ca' Granda Maggiore Hospital Polyclinic (Epiexome grant). E.T.P. was supported by an American Epilepsy Society–NORSE Institute grant.
Publisher Copyright:
© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
PY - 2022/11
Y1 - 2022/11
N2 - Objective: This study was undertaken to develop consensus-based recommendations for the management of adult and pediatric patients with new onset refractory status epilepticus (NORSE)/febrile infection-related epilepsy syndrome (FIRES) based on best evidence and experience. Methods: The Delphi methodology was followed. A facilitator group of nine experts was established, who defined the scope, users, and suggestions for recommendations. Following a review of the current literature, recommendation statements concerning diagnosis, treatment, and research directions were generated, which were then rated on a scale of 1 (strongly disagree) to 9 (strongly agree) by a panel of 48 experts in the field. Consensus that a statement was appropriate was reached if the median score was ≥7 and inappropriate if the median score was ≤3. The analysis of evidence was mapped to the results of each statement included in the Delphi survey. Results: Overall, 85 recommendation statements achieved consensus. The recommendations are divided into five sections: (1) disease characteristics; (2) diagnostic testing and sampling; (3) acute treatment; (4) treatment in the postacute phase; and (5) research, registries, and future directions in NORSE/FIRES. The detailed results and discussion of all 85 statements are outlined herein. A corresponding summary of findings and practical flowsheets are presented in a companion article. Significance: This detailed analysis offers insight into the supporting evidence and the current gaps in the literature that are associated with expert consensus statements related to NORSE/FIRES. The recommendations generated by this consensus can be used as a guide for the diagnosis, evaluation, and management of patients with NORSE/FIRES, and for planning of future research.
AB - Objective: This study was undertaken to develop consensus-based recommendations for the management of adult and pediatric patients with new onset refractory status epilepticus (NORSE)/febrile infection-related epilepsy syndrome (FIRES) based on best evidence and experience. Methods: The Delphi methodology was followed. A facilitator group of nine experts was established, who defined the scope, users, and suggestions for recommendations. Following a review of the current literature, recommendation statements concerning diagnosis, treatment, and research directions were generated, which were then rated on a scale of 1 (strongly disagree) to 9 (strongly agree) by a panel of 48 experts in the field. Consensus that a statement was appropriate was reached if the median score was ≥7 and inappropriate if the median score was ≤3. The analysis of evidence was mapped to the results of each statement included in the Delphi survey. Results: Overall, 85 recommendation statements achieved consensus. The recommendations are divided into five sections: (1) disease characteristics; (2) diagnostic testing and sampling; (3) acute treatment; (4) treatment in the postacute phase; and (5) research, registries, and future directions in NORSE/FIRES. The detailed results and discussion of all 85 statements are outlined herein. A corresponding summary of findings and practical flowsheets are presented in a companion article. Significance: This detailed analysis offers insight into the supporting evidence and the current gaps in the literature that are associated with expert consensus statements related to NORSE/FIRES. The recommendations generated by this consensus can be used as a guide for the diagnosis, evaluation, and management of patients with NORSE/FIRES, and for planning of future research.
KW - Delphi
KW - adult
KW - antiseizure medication
KW - epilepsy
KW - immunotherapy
KW - ketogenic diet
KW - pediatric
KW - refractory status epilepticus
KW - status epilepticus
UR - http://www.scopus.com/inward/record.url?scp=85138882054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138882054&partnerID=8YFLogxK
U2 - 10.1111/epi.17397
DO - 10.1111/epi.17397
M3 - Article
C2 - 35997591
AN - SCOPUS:85138882054
SN - 0013-9580
VL - 63
SP - 2840
EP - 2864
JO - Epilepsia
JF - Epilepsia
IS - 11
ER -